BIOTECHNOLOGY

When start-ups & biotech collide

Finfeed Archived Nov 29, 2018

The Australian biotech industry is heavily supported by government and could reach $8 billion in revenue this year.

Rhythm moves into next growth phase, appoints new CEO

Finfeed Archived Nov 28, 2018

Medical diagnostics pioneer, Rhythm Biosciences (ASX: RHY), has made some senior management changes, appointing Glenn Gilbert as its CEO, effective immediately.

ANP: Why partnering with big biotech has its benefits

Finfeed Archived Nov 22, 2018

Antisense Therapeutics (ASX:ANP) CEO Mark Diamond speaks about ANP's relationship with biotech Ionis Pharmaceuticals and how ANP has grown up.

Immuron appoints a new CEO to lead it into the future

Finfeed Archived Nov 19, 2018

Immuron (ASX:IMC) has just appointed a well-credentialled CEO to help it develop and commercialise its many treatments of many gut mediated diseases.

Imugene's gastric cancer immuno-oncology trial advances to Phase 2

Finfeed Archived Nov 13, 2018

Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced preparations are underway to begin the Phase 2 study of its HER-Vaxx cancer vaccine in gastric cancer patients in early 2019.

Good run continues for Imugene with $1.85M R&D tax incentive

Finfeed Archived Nov 09, 2018

Imugene Limited (ASX:IMU) has today announced that it has received a research and development (R&D) tax refund of $1.85 million as part of the Australian government’s R&D tax incentive scheme. The incentive recognises the important immuno-oncology research activities undertaken by the ASX small cap during the financial year ended 30 June 2018.

Prescient onboards former Array Biopharma executive

Finfeed Archived Oct 29, 2018

Clinical-stage oncology company, Prescient Therapeutics Ltd (ASX:PTX), has appointed leading drug discovery and development executive, Dr James Winkler, as Vice President for business development based in the US.

Breakthrough Prize given to Antisense pioneer

Finfeed Archived Oct 24, 2018

Last week, biopharmaceutical drug discovery and development company, Antisense Therapeutics (ASX:ANP) spiked 217% in one day

Biotech surges & pot-stocks reach new highs

Finfeed Archived Oct 22, 2018

It was a powerhouse week for biotech and pot-stocks, with high impact performances begging the question: is biotech finally back?

Antisense rally prompts question: ‘Are ASX Biotechs back?’

Finfeed Archived Oct 17, 2018

The biotech sector was yesterday led by biopharmaceutical drug discovery and development company, Antisense Therapeutics (ASX:ANP) which ended the day 217% higher.

Antisense Therapeutics could fill Duchenne Muscular Dystrophy treatment gap

Finfeed Archived Oct 04, 2018

Antisense Therapeutics’ (ASX:ANP) ATL1102 to treat inflammation in boys with Duchenne Muscular Dystrophy (DMD) - one of the most common fatal genetic disorders. It’s caused by a mutation in the muscle dystrophin gene leading to severe progressive muscle loss and premature death.

Biotechnology